Modifications of LFTs over time in patients with SSc-ILD treated with nintedanib in combination with RTX
| Baseline | 6 months | P value | Baseline | 12 months | P value | |
| %predicted FVC | 64±16 | 66±15 (13 patients) | 0.278 | 68±16 | 66±10 (7 patients) | 0.581 |
| %predicted TLC | 60±14 | 58±9 (13 patients) | 0.636 | 62±13 | 56±8 (7 patients) | 0.129 |
| % predicted DLCO | 48±20 | 46±14 (13 patients) | 0.489 | 45±13 | 39±12 (7 patients) | 0.155 |
DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; ILD, interstitial lung disease; LFTs, lung function tests; RTX, rituximab; SSc, systemic sclerosis; TLC, total lung capacity.